Progyny/$PGNY
1D1W1MYTD1Y5YMAX
Capital at risk
About Progyny
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
- Ticker
- $PGNY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 846
- Headquarters
- New York, United States
- Website
- www.progyny.com
Progyny Metrics
BasicAdvanced
$2.1B
29.91
$0.91
1.02
-
Price and volume
Market cap
$2.1B
Beta
1.02
52-week high
$33.07
52-week low
$16.10
Average daily volume
1.2M
Financial strength
Current ratio
2.137
Quick ratio
2.059
Long term debt to equity
0.05
Total debt to equity
0.05
Profitability
EBITDA (TTM)
125.572
Gross margin (TTM)
24.57%
Net profit margin (TTM)
6.00%
Operating margin (TTM)
9.14%
Effective tax rate (TTM)
34.38%
Revenue per employee (TTM)
$1,550,000
Management effectiveness
Return on assets (TTM)
10.14%
Return on equity (TTM)
16.24%
Valuation
Price to earnings (TTM)
29.909
Price to revenue (TTM)
1.71
Price to book
4.6
Price to tangible book (TTM)
4.87
Price to free cash flow (TTM)
12.562
Free cash flow yield (TTM)
7.96%
Free cash flow per share (TTM)
2.16
Growth
Revenue change (TTM)
5.54%
Earnings per share change (TTM)
55.39%
3-year revenue growth (CAGR)
11.04%
3-year earnings per share growth (CAGR)
22.78%
What the Analysts think about Progyny
Analyst ratings (Buy, Hold, Sell) for Progyny stock.
Analyst projections of the future price of Progyny stock.
Bulls say / Bears say
Q2 2026 showed improving operating performance: revenue rose 5.3% year over year, or 11.0% excluding the lost large client, while gross margin expanded to 25.5% from 23.7% and adjusted EBITDA margin improved to 17.7%. (Progyny)
Demand and retention indicators were favorable entering the selling season: Progyny reported new lives and early commitments pacing meaningfully ahead of the prior year and said it had removed most retention risk among its largest accounts; full-year 2026 revenue guidance implies 9.7%–11.7% growth excluding the prior-year transition revenue. (Progyny)
Progyny Select broadens the addressable market by offering small employers a fully insured, fixed-premium fertility and women’s-health plan, with distribution through brokers and health-plan partners for 2027 plan years. (Progyny)
Reported growth remains exposed to customer concentration: Progyny said a previously disclosed large client generated $17.2 million of revenue in Q2 2025 but none in Q2 2026, demonstrating how non-renewals can materially affect results. (Progyny)
Utilization-driven economics create execution risk: six-month ART cycles fell to 32,645 from 33,098 year over year even as average members increased, and the company warns that unexpectedly high consumption or adverse utilization mix can pressure client budgets and profitability. (SEC)
Progyny faces intensifying competition and industry consolidation, while clients may prefer integrated healthcare solutions over a standalone fertility benefit; the company also identifies increasing scrutiny of Progyny Rx’s PBM operations as a potential headwind. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Progyny Financial Performance
Revenues and expenses
Progyny Earnings Performance
Company profitability
Upcoming events
No upcoming events
Progyny News
AllArticlesVideos
Funds containing Progyny
AllUSDGBPEUR
Fund name | Fund size | $PGNY weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.11% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.